CA2833515C - High-affinity, dimeric inhibitors of psd-95 as efficient neuroprotectants against ischemic brain damage and for treatment of pain - Google Patents

High-affinity, dimeric inhibitors of psd-95 as efficient neuroprotectants against ischemic brain damage and for treatment of pain Download PDF

Info

Publication number
CA2833515C
CA2833515C CA2833515A CA2833515A CA2833515C CA 2833515 C CA2833515 C CA 2833515C CA 2833515 A CA2833515 A CA 2833515A CA 2833515 A CA2833515 A CA 2833515A CA 2833515 C CA2833515 C CA 2833515C
Authority
CA
Canada
Prior art keywords
peptide
psd
linker
cpp
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2833515A
Other languages
English (en)
French (fr)
Other versions
CA2833515A1 (en
Inventor
Anders Bach
Kristian Stromgaard
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Københavns Universitet
Original Assignee
Københavns Universitet
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Københavns Universitet filed Critical Københavns Universitet
Publication of CA2833515A1 publication Critical patent/CA2833515A1/en
Application granted granted Critical
Publication of CA2833515C publication Critical patent/CA2833515C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
CA2833515A 2011-05-13 2012-05-11 High-affinity, dimeric inhibitors of psd-95 as efficient neuroprotectants against ischemic brain damage and for treatment of pain Active CA2833515C (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201161485898P 2011-05-13 2011-05-13
US61/485,898 2011-05-13
EP11165994 2011-05-13
EP11165994.2 2011-05-13
PCT/EP2012/058762 WO2012156308A1 (en) 2011-05-13 2012-05-11 High-affinity, dimeric inhibitors of psd-95 as efficient neuroprotectants against ischemic brain damage and for treatment of pain

Publications (2)

Publication Number Publication Date
CA2833515A1 CA2833515A1 (en) 2012-11-22
CA2833515C true CA2833515C (en) 2017-11-28

Family

ID=44367299

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2833515A Active CA2833515C (en) 2011-05-13 2012-05-11 High-affinity, dimeric inhibitors of psd-95 as efficient neuroprotectants against ischemic brain damage and for treatment of pain

Country Status (13)

Country Link
EP (1) EP2707014B1 (https=)
JP (1) JP6084207B2 (https=)
KR (1) KR102046830B1 (https=)
CN (1) CN103533949B (https=)
AU (1) AU2012257774C1 (https=)
BR (1) BR112013029206B1 (https=)
CA (1) CA2833515C (https=)
DK (1) DK2707014T3 (https=)
ES (1) ES2544573T3 (https=)
IL (1) IL228893B (https=)
PL (1) PL2707014T3 (https=)
SG (1) SG194717A1 (https=)
WO (1) WO2012156308A1 (https=)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2014356912B2 (en) 2013-12-01 2019-08-01 University Of Copenhagen Fatty acid derivatives of dimeric inhibitors of PSD-95
CN103804500B (zh) * 2014-01-22 2015-12-30 广州军区广州总医院 用于治疗慢性疼痛的多肽
CN106661126B (zh) * 2014-05-28 2021-12-10 诺诺公司 TAT-NR2B9c的氯盐
BR112020000115A2 (pt) * 2017-07-05 2020-07-07 Biocells (Beijing) Biotech Co., Ltd. sais farmaceuticamente aceitáveis de polipeptídeos e uso dos mesmos
JP7073486B2 (ja) 2017-09-30 2022-05-23 ▲拝▼西欧斯（北京）生物技▲術▼有限公司 興奮性神経毒性に関連した損傷の治療用ペプチド組成物
CA3089161A1 (en) * 2018-02-02 2019-08-08 Kobenhavns Universitet Compounds for the treatment of acute brain injury
CN110627877A (zh) * 2019-09-25 2019-12-31 成都奥达生物科技有限公司 一种psd-95抑制剂
CN110787284A (zh) * 2019-11-23 2020-02-14 胡书群 一种治疗缺血性脑损伤的混合小肽tat-shc及其应用
WO2021119756A1 (en) * 2019-12-20 2021-06-24 PYC Therapeutics Limited Novel cellular delivery methods
CN111285923B (zh) * 2020-03-05 2023-02-03 成都奥达生物科技有限公司 一种psd-95抑制剂
US20230346948A1 (en) * 2020-03-06 2023-11-02 University Of Copenhagen Lipid conjugated peptide inhibitors of PICK1
CA3203688A1 (en) * 2021-01-08 2022-07-14 Jonathan David Garman Plasmin-resistant peptides for improved therapeutic index
TW202306965A (zh) 2021-05-12 2023-02-16 哥本哈根大學 Ｐｓｄ－９５抑制劑及其用途
CN114533874B (zh) * 2022-01-27 2023-12-29 北京和舆医药科技有限公司 Psd-95 gk结构域作为神经保护靶点的用途
EP4706670A1 (en) * 2023-04-26 2026-03-11 Shenzhen Salubris Pharmaceuticals Co., Ltd. Psd-95 domain inhibitor, and preparation method therefor and use thereof
CN119569824A (zh) * 2023-09-07 2025-03-07 湖南中晟全肽生物科技股份有限公司 作为神经保护剂的药用化合物及其应用
CN118027156B (zh) * 2023-09-07 2024-11-05 湖南中晟全肽生物科技股份有限公司 一种psd-95抑制剂及其用途
CN117164725B (zh) * 2023-09-07 2024-05-10 湖南中晟全肽生物科技股份有限公司 一种突触后密度蛋白-95抑制剂多肽
WO2025215348A1 (en) * 2024-04-08 2025-10-16 The Boots Company Plc Skin wound treatment

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7510824B2 (en) * 1999-06-02 2009-03-31 Nono Inc. Method of screening peptides useful in treating traumatic injury to the brain or spinal cord
EP2089052A4 (en) 2006-05-24 2011-02-16 Peg Biosciences POLYETHYLENE GLYCOL-BASED LINK COMPOUNDS AND BIOLOGICALLY ACTIVE CONJUGATES BASED ON SAID COMPOUNDS
WO2008008348A2 (en) * 2006-07-11 2008-01-17 Arbor Vita Corporation Method and compositions for treating stroke with fever
US8080518B2 (en) * 2007-12-05 2011-12-20 Arbor Vita Corporation Co-administration of an agent linked to an internalization peptide with an anti-inflammatory
WO2010004003A2 (en) * 2008-07-09 2010-01-14 University Of Copenhagen Modified peptides as potent inhibitors of the psd-95/nmda receptor interaction

Also Published As

Publication number Publication date
BR112013029206A2 (pt) 2017-02-14
AU2012257774C1 (en) 2016-11-03
CA2833515A1 (en) 2012-11-22
SG194717A1 (en) 2013-12-30
EP2707014A1 (en) 2014-03-19
EP2707014B1 (en) 2015-06-17
KR102046830B1 (ko) 2019-11-20
AU2012257774B2 (en) 2016-07-28
BR112013029206B1 (pt) 2021-05-04
CN103533949A (zh) 2014-01-22
KR20140038435A (ko) 2014-03-28
IL228893B (en) 2018-01-31
IL228893A0 (en) 2013-12-31
JP2014514365A (ja) 2014-06-19
AU2012257774A1 (en) 2013-11-07
CN103533949B (zh) 2015-11-25
PL2707014T3 (pl) 2015-12-31
WO2012156308A1 (en) 2012-11-22
ES2544573T3 (es) 2015-09-01
DK2707014T3 (en) 2015-09-14
JP6084207B2 (ja) 2017-02-22

Similar Documents

Publication Publication Date Title
CA2833515C (en) High-affinity, dimeric inhibitors of psd-95 as efficient neuroprotectants against ischemic brain damage and for treatment of pain
US9139615B2 (en) High-affinity, dimeric inhibitors of PSD-95 as efficient neuroprotectants against ischemic brain damage and for treatment of pain
EP2064234A2 (en) Bioactive peptides and method of using same
Sulochana et al. Developing antiangiogenic peptide drugs for angiogenesis-related diseases
TW202000686A (zh) 補體抑制素(compstatin)類似物及其醫藥用途
CA2559838A1 (en) Y2 selective receptor agonists for therapeutic interventions
US10441628B2 (en) High activity tumour inhibitor and preparation method and use thereof
JP6952320B2 (ja) 新規ｎｋ３受容体アゴニスト
US7408028B2 (en) Peptides, antibodies thereto, and their use in treatment of central nervous system, damage
EP2552940A2 (en) Peptides for promoting angiogenesis and an use thereof
JP6143270B2 (ja) マイオスタチン阻害ペプチド
US9815867B2 (en) Peptide for inhibiting vascular endothelial growth factor receptor
WO2021098996A1 (en) Oligopeptides that inhibit angiogenesis and vascular function
ES2541308T3 (es) Agonistas y antagonistas completos y parciales altamente potentes del receptor de nociceptina/orfanina FQ
US9408888B2 (en) High affinity bivalent helically constrained peptide against cancer
KR20160140147A (ko) 심장 허혈후 재관류 손상에 의한 심장 질환 치료 및 예방용 조성물

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20170317

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 13TH ANNIV.) - STANDARD

Year of fee payment: 13

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250414

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250414

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 14TH ANNIV.) - STANDARD

Year of fee payment: 14

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20260423

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20260423